Roche’s Oral Breast Cancer Drug Disappoints in Phase II Study

April 25, 2022

The pharma manufacturer Roche has announced discouraging results for its oral breast cancer drug giredestrant. Results show that the drug failed on the study’s primary endpoint of improving progress-free survival for ER-positive, HER2-negative patients, although investigators state that efficacy data was improved for patients with “higher dependence on estrogen receptor activity. This isn’t the first setback for the class of drugs, called selective estrogen receptor degraders (SERD), as Sanofi’s latest oral SERD for breast cancer announced similarly negative results earlier this year.

In addition, according to John Carroll of Endpoints News, “Radius Health was hammered late last year after the biotech revealed its own positive oral SERD data for elacestrant, which was quickly punished by investors after they poured through the unimpressive details. Where researchers did see a significant impact was in ESR1 patients.”

To learn more, click here.